Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Epitomics names chief scientific officer
Dr An comes to Epitomics from Merck Research Laboratories, where he was director of biologics research. He has over 12 years of experience in drug discovery and development
Dr An comes to Epitomics from Merck Research Laboratories, where he was director of biologics research. He has over 12 years of experience in drug discovery and development
Colin Garner, founder of Xceleron is retiring from the president/CEO position and will now serve as the senior scientific advisor to Xceleron and a non-executive director. Mr Butler
The new five-story hospital complex to be built in Makkah is part of Saudi Arabia’s Ministry of Health’s SR1 billion Makkah Al-Mukarrama Medical City project. It will be
The new division will utilize Dip Pen Nanolithography nanofabrication techniques, in combination with proprietary detection systems, to produce uniquely sensitive assays for protein discovery and identification. Femtofluidics handling
The topical anesthetic product is used in a variety of hospital and outpatient settings. And the Amantadine HCl brand is equivalent to Symmetrel, a registered trademark of Endo
3M has operations in six business segments. It offers a range of feasibility, development and manufacturing capabilities combined with regulatory guidance to help bring products to market. It
The two molecules of cancer are Exelixis’s XL184, a small molecule inhibitor of MET, VEGFR2 and RET, which is currently in Phase III development for medullary thyroid cancer;
The study results are from a pooled analysis of approximately 2,000 patients enrolled in two Phase III clinical trials of Ixempra (046 and 048). Patients studied were either
The DNA Repair Company (DNAR) study was conducted in collaboration with investigators from the Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center, both in Boston. The study
In the recently-completed Phase IIa clinical trial, daily doses of LX6171 or placebo were given to 121 healthy elderly subjects with age-associated memory impairment. The study evaluated safety,